On the Record · Pfizer
Pfizer competitors, on the record
The companies whose own annual reports name Pfizer as a competitor, each with the sentence it appears in and the filing it came from.
Who Pfizer names
Pfizer’s annual reports for 2022 to 2025 describe its competition by kind of business and do not name competing companies.
Who names Pfizer
Companies whose own annual reports name Pfizer as a competitor.
Word for word“For example, AMVUTTRA for the treatment of ATTR amyloidosis with cardiomyopathy, competes with VYNDAQEL/VYNDAMAX (tafamidis), which is marketed by Pfizer, and ATTRUBY (acoramidis), which is marketed by BridgeBio, both of which are approved to treat ATTR amyloidosis with cardiomyopathy.” 10-K for 2025
Word for word“Our principal competitors in the generic and biosimilar pharmaceutical market include Teva Pharmaceutical Industries Ltd., Viatris Inc., Sandoz Group, Pfizer Inc., Fresenius Kabi KGaA, Hikma Pharmaceuticals PLC, Dr. Reddy's Laboratories Ltd., Amphastar Pharmaceuticals, Inc., Sun Pharmaceutical Industries Ltd., Lupin Pharmaceuticals, Inc., Zydus Pharmaceuticals USA Inc., and Aurobindo Pharma Limited.” 10-K for 2025
Word for word“A number of companies, including some mid-to-large biopharmaceutical companies, such as Alnylam Pharmaceuticals, Bayer AG, Novo Nordisk, CSL Ltd., Pfizer Inc., Roche Holding AG, Sanofi Genzyme and Shire Plc., currently market or are pursuing the development of products for the treatment of hemophilia.” 10-K for 2017
Word for word“Other forms of testosterone replacement therapy include injectables such as Endo’s Aveed ® and Pfizer’s Depo®-Testosterone, surgically implanted Testopel ® pellets by Endo and intranasal Natesto ® .” 10-K for 2025
Word for word“Vyndaqel/Vyndamax (Tafamidis and tafamidis meglumine) Pfizer A small molecule medicine to stabilize TTR protein” 10-K for 2025
Word for word“Additionally, there are a number of Phase 3 compounds (dazukibart (anti-IFN; Pfizer), anifrolumab (Saphnelo®; anti-IFN; AstraZeneca) and efartigimod (Vyvgart®; anti-FcRn; Argenx) which could launch before the end of the decade.” 20-F for 2025
Word for word“We largely compete against Pfizer and BioNTech for sales of our COVID vaccines, whose vaccine is also based on mRNA technology.” 10-K for 2025
Word for word“The major market players within the intranasal drug market and our primary competitors in the United States and abroad include ADAPT Pharma, Inc., Teva Pharmaceuticals Ltd., Pfizer Inc., Viatris Inc., and Kaléo, Inc., among others.” 20-F for 2025
Word for word“Several competitors are working on developing seasonal influenza vaccines using different technologies than those in existing marketed vaccines, the most notable being mRNA from companies including Moderna and Pfizer.” 10-K for 2025
Word for word“Vyndaqel (tafamids meglumine) and Vyndamax (tafamidis) are commercialized in the United States, EU and some countries in Latin America by Pfizer.” 10-K for 2025
Word for word“The principal sources of competition for ADVATE and ADYNOVATE globally are: XYNTHA/REFACTO AF (Pfizer and SOBI); KOGENATE (Bayer); HELIXATE (CSL); KOVALTRY (Bayer); Iblias (CSL); ELOCTATE/ELOCTA (Bioverativ and SOBI); NOVOEIGHT (Novo Nordisk); and NUWIQ (Octapharma); Afstyla (CSL).” 10-K for 2017
Read from Pfizer’s annual reports (10-K for 2025, 10-K for 2024, 10-K for 2023, 10-K for 2022) and the financial data it files with the SEC, as of 2026-02-26. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.